Get started
Author

Marina Riggio

Observed names: M. Riggio, Riggio, Marina
OpenAlex ID: A5086280832
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins
2017 · Marina Riggio, María C. Perrone, et al. · Scientific Reports · 136
PDF
FGF2 induces breast cancer growth through ligand‐independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences
2019 · Sebastián Giulianelli, Marina Riggio, et al. · International Journal of Cancer · 67
PDF
PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer
2011 · Marina Riggio, María Laura Polo, et al. · Carcinogenesis · 48
PDF
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA / PRB ratio via AIB 1 or SMRT recruitment to the CCND 1 and MYC promoters
2014 · Victoria Wargon, Marina Riggio, et al. · International Journal of Cancer · 40
PDF
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
2023 · María Jimena Rodriguez, María Cecilia Perrone, et al. · Scientific Reports · 34
PDF
Molecular mechanisms underlying AMH elevation in hyperoestrogenic states in males
2020 · Clara Valeri, María M. Lovaisa, et al. · Scientific Reports · 28
PDF
Responsiveness to PI3K and MEK Inhibitors in Breast Cancer. Use of a 3D Culture System to Study Pathways Related to Hormone Independence in Mice
2010 · Maria Laura Polo, Maria Victoria Arnoni, et al. · PLoS ONE · 28
PDF
Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
2015 · María Laura Polo, Marina Riggio, et al. · Oncotarget · 26
PDF
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1
2021 · María Florencia Abascal, Andrés Elia, et al. · International Journal of Cancer · 14
Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
2025 · María Laura Polo, Marina Riggio, et al. · Oncotarget
PDF
mTOR inhibition in the treatment of resistant breast cancer
2019 · M.J. Rodriguez, M.C. Perrone, et al. · Annals of Oncology
PDF
Rol de la vía PI3K/AKT/mTOR en la progresión del cáncer de mama
2016 · Marina Riggio · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Abstract A70: Akt2 gain or Akt1 loss drives invasion and aggressiveness in breast cancer
2016 · Cecilia Perrone, Marina Riggio, et al. · Molecular Cancer Research
Abstract 1403: Early tumor regression after endocrine and kinase inhibitor therapy in an experimental model of breast cancer.
2013 · Maria Laura Polo, Marina Riggio, et al. · Cancer Research
Abstract 1387: The ratio of progesterone receptor isoforms predicts progestin and antiprogestin response: Interaction of PR with AIB1 or SMRT.
2013 · Marina Riggio, Sebastián Giulianelli, et al. · Cancer Research
Crecimiento del cáncer de mama dependiente de receptores hormonales: aportes de un modelo experimental
2011 · Claudia Lanari, Virginia Novaro, et al. · Americanae (AECID Library)
Abstract 1316: Overactivation of AKT promotes hormone-independent mammary tumors
2011 · Marina Riggio, Laura Polo, et al. · Cancer Research
Abstract 1319: Early tumor regression after endocrine and kinase inhibitor treatments in mammary carcinomas with different hormonal requirements
2011 · Maria Laura Polo, Marina Riggio, et al. · Cancer Research
Works count: 22
Citation count: 422
H-index: 9
I10-index: 9
Year
Topic
Type